Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016972 · ClinicalTrials.gov registry record · Phase 2
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
A Phase 2 study, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT06016972: Completed Phase 2 study, sponsored by Qlaris Bio.
NCT06016972 is a Phase 2 study that has completed, run by Qlaris Bio. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06016972, a Phase 2 study, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
Primary Outcome
Ocular safety and tolerability: adverse events (AEs)
Interventions
- DRUG Experimental: QLS-111 ophthalmic solution, (0.015%)
- DRUG Experimental: QLS-111 ophthalmic solution, (0.03%)
- DRUG Experimental: QLS-111 ophthalmic solution, (0.075%)
- OTHER QLS-111 ophthalmic vehicle solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-03-05 |
| Est. Completion | 2024-08-20 |
| Phase | Phase 2 |
What the finished NCT06016972 record still lists
NCT06016972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 4 interventions - of which Experimental: QLS-111 ophthalmic solution, (0.015%) is the first listed.
NCT06016972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06016972 about?
NCT06016972 is a clinical study titled "Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients". Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
What is the current status of trial NCT06016972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2024-03-05. Estimated completion is 2024-08-20.
What interventions are being tested in trial NCT06016972?
The interventions under investigation include: Experimental: QLS-111 ophthalmic solution, (0.015%) (DRUG), Experimental: QLS-111 ophthalmic solution, (0.03%) (DRUG), Experimental: QLS-111 ophthalmic solution, (0.075%) (DRUG), QLS-111 ophthalmic vehicle solution (OTHER).
Who is sponsoring clinical trial NCT06016972?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06016972's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI